Galderma SA, of Lausanne, Switzerland, said the FDA granted orphan designation to its trifarotene molecule for the treatment of congenital ichthyosis. Trifarotene is a selective agonist of the gamma retinoic acid receptor, which currently is in development for other more common dermatological conditions.